Published in Nat Rev Cancer on September 01, 2007
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Raising the bar for cancer therapy models. Nat Biotechnol (2010) 4.52
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov (2012) 4.30
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest (2012) 2.95
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev (2008) 2.74
Peto's Paradox: evolution's prescription for cancer prevention. Trends Ecol Evol (2011) 2.48
Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev (2010) 2.44
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A (2010) 2.20
The Mouse Tumor Biology database. Nat Rev Cancer (2008) 2.15
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J (2013) 2.01
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab (2014) 1.92
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89
Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol (2012) 1.87
Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature (2014) 1.86
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol (2009) 1.79
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell (2011) 1.74
A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci U S A (2008) 1.70
Retracted Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol (2012) 1.67
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov (2008) 1.59
Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res (2013) 1.53
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer (2010) 1.51
Chemical genetic screening in the zebrafish embryo. Nat Protoc (2009) 1.49
Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer (2009) 1.47
Modeling metastasis in the mouse. Curr Opin Pharmacol (2010) 1.46
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release (2014) 1.46
Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One (2011) 1.43
In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc Natl Acad Sci U S A (2011) 1.42
Quantitative proteomics by metabolic labeling of model organisms. Mol Cell Proteomics (2009) 1.42
Institutional shared resources and translational cancer research. J Transl Med (2009) 1.41
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene (2008) 1.38
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res (2011) 1.32
Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer (2015) 1.32
Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. Transl Oncol (2010) 1.31
Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech (2010) 1.27
Stable RNA interference rules for silencing. Nat Cell Biol (2014) 1.26
Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions. Clin Cancer Res (2008) 1.26
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A (2011) 1.26
Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res (2008) 1.25
Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am J Pathol (2009) 1.22
Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res (2011) 1.21
MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma. Cancer Lett (2013) 1.19
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol (2014) 1.17
Neuroendocrine influences on cancer progression. Brain Behav Immun (2012) 1.15
Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One (2009) 1.15
Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol Pharm (2012) 1.14
Life in the fast lane: mammalian disease models in the genomics era. Cell (2012) 1.08
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res (2011) 1.07
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer (2010) 1.07
Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol (2010) 1.06
Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models. Dis Model Mech (2013) 1.05
A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res (2009) 1.03
Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev (2009) 1.02
Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS One (2011) 1.00
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol (2016) 0.99
A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev (2014) 0.99
Animal models and conserved processes. Theor Biol Med Model (2012) 0.99
Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer Prev Res (Phila) (2010) 0.99
ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res (2010) 0.99
Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1. Mol Cancer Res (2011) 0.98
Experimental models of hepatocellular carcinoma: developments and evolution. J Cancer Res Clin Oncol (2009) 0.98
Mouse models in liver cancer research: a review of current literature. World J Gastroenterol (2008) 0.98
Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med (2013) 0.97
Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin Cancer Biol (2011) 0.96
Alveolar type II cells possess the capability of initiating lung tumor development. PLoS One (2012) 0.96
Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system. Nat Protoc (2012) 0.96
Molecular characterization of mutant mouse strains generated from the EUCOMM/KOMP-CSD ES cell resource. Mamm Genome (2013) 0.96
Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res (2012) 0.96
A preclinical murine model of hepatic metastases. J Vis Exp (2014) 0.95
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther (2013) 0.95
The yin and yang of kidney development and Wilms' tumors. Genes Dev (2015) 0.95
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93
Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Front Chem (2014) 0.93
GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech (2015) 0.92
Endosialin expression in side populations in human sarcoma cell lines. Oncol Lett (2011) 0.92
The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila) (2008) 0.92
Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br J Pharmacol (2014) 0.92
Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des Devel Ther (2014) 0.92
Animal models in osteosarcoma. Front Oncol (2014) 0.91
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res (2013) 0.91
Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics (2008) 0.91
K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity. PLoS One (2011) 0.90
dbDEPC: a database of differentially expressed proteins in human cancers. Nucleic Acids Res (2009) 0.90
The use of GEM models for experimental cancer therapeutics. Dis Model Mech (2008) 0.89
Inactivation and inducible oncogenic mutation of p53 in gene targeted pigs. PLoS One (2012) 0.89
Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics Clin Appl (2011) 0.89
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol (2013) 0.89
Lymphatic response to depilation-induced inflammation in mouse ear assessed with label-free optical lymphangiography. Lasers Surg Med (2015) 0.88
A DNA transposon-based approach to validate oncogenic mutations in the mouse. Proc Natl Acad Sci U S A (2008) 0.88
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell (2005) 7.65
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Stromal biology and therapy in pancreatic cancer. Gut (2010) 3.80
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 3.13
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell (2009) 2.82
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest (2011) 2.60
The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res (2006) 2.48
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell (2007) 2.36
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A (2013) 1.88
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev (2007) 1.81
Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res (2007) 1.80
What we have learned about pancreatic cancer from mouse models. Gastroenterology (2012) 1.78
K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods Enzymol (2008) 1.78
Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology (2011) 1.63
Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut (2011) 1.58
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J Clin Invest (2011) 1.58
Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut (2012) 1.55
Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell (2010) 1.51
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res (2007) 1.47
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med (2013) 1.40
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood (2006) 1.35
C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov (2011) 1.27
Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res (2005) 1.26
Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther (2004) 1.25
Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res (2006) 1.24
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut (2013) 1.21
Ras redux: rethinking how and where Ras acts. Curr Opin Genet Dev (2003) 1.21
RAS in cellular transformation and senescence. Eur J Cancer (2009) 1.21
A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. Cancer Chemother Pharmacol (2011) 1.15
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med (2012) 1.14
Predictive in vivo animal models and translation to clinical trials. Drug Discov Today (2012) 1.12
The promise and perils of antioxidants for cancer patients. N Engl J Med (2014) 1.06
Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev (2009) 1.02
Physiological analysis of oncogenic K-ras. Methods Enzymol (2006) 0.96
The use of GEM models for experimental cancer therapeutics. Dis Model Mech (2008) 0.89
Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev Res (Phila) (2010) 0.89
RhoC interacts with integrin α5β1 and enhances its trafficking in migrating pancreatic carcinoma cells. PLoS One (2013) 0.88
VAV1: a new target in pancreatic cancer? Cancer Biol Ther (2005) 0.87
Finding and killing the CRABs of pancreatic cancer. Gastroenterology (2009) 0.83
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS One (2013) 0.82
Detecting and diagnosing ampullary neoplasms. Cancer Biol Ther (2004) 0.82
Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Pancreatology (2011) 0.82
Targeting oncogene dependence and resistance. Cancer Cell (2003) 0.79
An shRNA silencing a non-toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell. J Cell Physiol (2009) 0.78
In search of an early warning system for pancreatic cancer. Cancer Biol Ther (2003) 0.76
Corrigendum: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat Cell Biol (2016) 0.75
Quid pro Quo: A Tumor is Not Alone. Trends Mol Med (2017) 0.75